Randomized Study Comparing MR-guided in Bore Versus MRI/US Fusion-guided Prostate Biopsy
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring MRI/US fusion-guided prostate biopsy, MR-guided in-bore prostate biopsy, prostate cancer
Eligibility Criteria
Inclusion Criteria:
- At least one prior negative prostate biopsy
- Prostate-specific antigen (PSA) > 4 ng/ml
Exclusion Criteria:
- Known prostate cancer
- Contraindications against MRI
- Contraindications against prostate biopsy
Sites / Locations
- University Hospital Düsseldorf
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
A: MR-guided in-bore prostate biopsy
B: MRI/US fusion-guided prostate biopsy
Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)